Medical Therapy. Efficacy or Lack of Efficacy

Successful Completion of High-Risk Neuroblastoma Therapy After Stabilization of Pulmonary Hypertension With Tadalafil

Takuma Sugahara, Hirohito Kubota, Tatsuya Kamitori, Koichi Matsuda, Shiro Baba, Katsutsuga Umeda, Junko TakitaKyoto University.Japan Pediatric InternationalPediatr Int 2026; DOI: 10.1111/ped.70427 AbstractAbstract Not Available CategoryMedical Therapy. Efficacy or Lack of Efficacy Age Focus: Pediatric Pulmonary Vascular Disease Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication Article Access Free PDF File or Full

Successful Completion of High-Risk Neuroblastoma Therapy After Stabilization of Pulmonary Hypertension With Tadalafil Read More »

Pediatric Pulmonary Hypertension: A Systematic Approach

Andrew Corson, Ranjit Philip, Neil Tailor, Abhishek Chakraborty, Kaitlynn Littleford, Grace McCormick, Aaron WalshLe Bonheur Children’s Hospital and University of Tennessee Health Science Center College of Medicine.United States Journal of the American College of Cardiology Case ReportsJACC Case Rep 2026;DOI: 10.1016/j.jaccas.2026.108135 AbstractBackground: Pediatric pulmonary hypertension comprises a variety of etiologies across different age groups, requiring a systematic

Pediatric Pulmonary Hypertension: A Systematic Approach Read More »

Sotatercept in Children with Pulmonary Hypertension-A Narrative Review

Johanna Schulz, Veronika C. Stark, Lars Harbaum, Rainer Kozlik-Feldmann, Thomas S. Mir, Fridrike Stute, Jakob OlfeUniversity Heart & Vascular Center Hamburg. University Medical Centre Hamburg-Eppendorf Hamburg.Germany ChildrenChildren 2026; 13: DOI: 10.3390/children13040465 AbstractBackground/objectives: Pulmonary arterial hypertension (PAH) is a rare but life-threatening disease that presents particular therapeutic challenges in children. It is characterized by pulmonary vasoconstriction and vascular

Sotatercept in Children with Pulmonary Hypertension-A Narrative Review Read More »

H2S Donor Therapy Reverses Established Pulmonary Arterial Hypertension and Pulmonary Vascular Structural Remodeling in Rats

Jie Zheng, Yanan Zhang, Boyang Lv, Yuanyuan Ma, Xuecong Zhong, Junbao Du, Hongfang Jin, Yaqian HuangPeking University First Hospital and Peking University.China BiomedicinesBiomedicines 2026;DOI: 10.3390/biomedicines14040760 AbstractObjectives: Downregulation of the endogenous gasotransmitter hydrogen sulfide (H2S) contributes to the pathogenesis of pulmonary arterial hypertension (PAH). While prophylactic H2S supplementation prevents PAH initiation in different rat models, its ability

H2S Donor Therapy Reverses Established Pulmonary Arterial Hypertension and Pulmonary Vascular Structural Remodeling in Rats Read More »

A child with cobalamin C deficiency caused by complex heterozygous variation of c.567dupT and c.80A > G complicated with pulmonary arterial hypertension and hydrocephalus: A case report and literature review

Cui, Xuxia, Zhong, Yajing, Yin, ChongjuanFirst Hospital of Shanxi Medical University.China MedicineMedicine 2026; 105: DOI: 10.1097/MD.0000000000048340 AbstractRationale: Cobalamin C (cblC) deficiency is one of the most common congenital vitamin B12 metabolic abnormalities, and may cause severe neurologic symptoms, gastrointestinal and nephritic symptoms.Patient concerns: A 9-month-old boy presented with a 10-day history of progressive dyspnea and weak cough, accompanied by

A child with cobalamin C deficiency caused by complex heterozygous variation of c.567dupT and c.80A > G complicated with pulmonary arterial hypertension and hydrocephalus: A case report and literature review Read More »

Inflachromene attenuates monocrotaline-induced pulmonary arterial hypertension by suppressing the HMGB1-TLR4/RAGE-NF-κB signaling pathway

Yueru Wang, Dina Nuerlan, Bilali Paizula, Yimuran Kawulijiang, Jiyao Chen, Hong Zhu, Wentao Xiao, Zhayier Tueraili, Guoming ZhangFirst Affiliated Hospital of Xinjiang Medical University. Second Affiliated Hospital of Xinjiang Medical University. First Affiliated Hospital of Shihezi University.China International ImmunopharmacologyInt Immunopharmacol 2026; DOI: 10.1016/j.intimp.2026.116712 AbstractPulmonary arterial hypertension (PAH) is a debilitating and fatal cardiovascular disorder marked by

Inflachromene attenuates monocrotaline-induced pulmonary arterial hypertension by suppressing the HMGB1-TLR4/RAGE-NF-κB signaling pathway Read More »

Treprostinil Is Associated With Early and Sustained Improvement in Group 3 Pulmonary Hypertension and Right Ventricular Function in Children

Kaushik Parvathaneni, Justin J. Kochanski, Megha D. Tandel, Esther Liu, Alisa Arunamata, Jeffrey A. Feinstein, Rachel K. HopperStanford University School of Medicine and Stanford University.United States Pulmonary CirculationPulm Circ 2026; 16: DOI: 10.1002/pul2.70304 AbstractUse of subcutaneous treprostinil (TRE) in children with pulmonary hypertension (PH) secondary to lung disease (group 3 PH) is not well described. We

Treprostinil Is Associated With Early and Sustained Improvement in Group 3 Pulmonary Hypertension and Right Ventricular Function in Children Read More »

Non-invasive nitric oxide use for pulmonary hypertension and pulmonary vascular disease associated with bronchopulmonary dysplasia in preterm infants

Aastha Chandra, Danielle R. Rios, Daniel Dagle, Patrick J. McNamara, Adrianne R. BischoffUniversity of Iowa.United States Journal of PerinatologyJ Perinatol 2026; DOI: 10.1038/s41372-026-02687-w AbstractAbstract Not Available CategoryClass III. Pulmonary Hypertension Associated with Lung DiseaseDiagnostic Testing for Pulmonary Vascular Disease. Non-invasive TestingMedical Therapy. Efficacy or Lack of Efficacy Age Focus: Pediatric Pulmonary Vascular Disease Fresh or Filed

Non-invasive nitric oxide use for pulmonary hypertension and pulmonary vascular disease associated with bronchopulmonary dysplasia in preterm infants Read More »

Outpatient Medication Prescribing Patterns in Bronchopulmonary Dysplasia: A Survey of Clinical Practices and Challenges

Michael C. Tracy, Joseph M. Collaco, Gangaram Akangire, Nicolas A. Bamat, Manvi Bansai, Sara K. Dawson, Lystra P. Hayden, Winston M. Manimtim, Antonia P. Popova, Demet Toprak, Sharon A. McGrath-Morrow, Paul E. MooreStanford University. Johns Hopkins University. Children’s Mercy Hospital. University of Missouri Kansas City School of Medicine. Children’s Hospital of Philadelphia and University of

Outpatient Medication Prescribing Patterns in Bronchopulmonary Dysplasia: A Survey of Clinical Practices and Challenges Read More »

Early Results of Sotatercept Treatment in Patients With Severe Pulmonary Hypertension and a Potts Shunt

Manish A. Aggarwal, Kelly Merrill, Delphine Yung, R. Mark GradyWashington University and St Louis Children’s Hospital. University of Washington and Seattle Children’s Hospital.United States Pulmonary CirculationPulm Circ 2026; 16: DOI: 10.1002/pul2.70296 AbstractTwelve patients with severe pulmonary hypertension (PH) who had a pulmonary artery-to-descending aorta (Potts) shunt were treated with the novel PH drug sotatercept for an

Early Results of Sotatercept Treatment in Patients With Severe Pulmonary Hypertension and a Potts Shunt Read More »

Scroll to Top